Govt eases loan licence requirement for 'outsourced' sterilisation of medical gear

Medical device makers now avoid loan licenses for outsourced sterilization services. This change simplifies business while industry leaders express concerns about new labeling rules. Printing sterilizer license numbers on device labels may hinder export flexibility and cause shipment delays. Manufacturers worry about losing the ability to choose the fastest available sterilization facility. The government also recognized the European Union for clinical investigation waivers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gTqpi32
via IFTTT

Read More

DRL, Emcure get approval to make breakthrough HIV drug

India's drug regulator has cleared the path for local lenacapavir manufacturing. Two Indian pharmaceutical companies received waivers for local clinical trials. This move will improve access to the HIV prevention injection. Lenacapavir is a breakthrough twice-yearly injection for HIV prevention. Patient groups had urged the regulator to expedite this process.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uDHPmRf
via IFTTT

Read More

Adani Group to set up 2,000-bed hospital in Bengal, 1,000 beds to be free

The Adani Group plans to establish a significant 2,000-bed hospital in New Town. Half of these beds will be allocated for free treatment of the poor. West Bengal Chief Minister Suvendu Adhikari confirmed this development. He stated that Karan Adani had met him regarding the project. Gautam Adani has sent a commitment letter to begin work soon.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fwDN7Sk
via IFTTT

Read More

USFDA ends inspection of Aurobindo Pharma arm's facility with 4 observations

Aurobindo Pharma announced its subsidiary Lannett Company LLC's facility inspection concluded. The US Food and Drug Administration conducted this routine inspection from August 17-21, 2026. Four procedural observations were noted during the Seymour, USA facility's review. The company will provide its response to the USFDA within the required timeframe.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vwhXlj3
via IFTTT

Read More

Indian pharma has little reason to fear Trump

US tariff threats on Indian generic drugs face significant obstacles. These duties could increase American healthcare costs and potentially cause shortages. Indian firms operate on low margins, making tariff absorption difficult. Recent US manufacturing experiences offer little incentive for relocation. Targeted incentives offer a more direct approach to supply chain resilience.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5tyzLi0
via IFTTT

Read More

Udan vs Udaan: Delhi court restrains pharmaceutical firm from using 'Udaan' mark

A Delhi court has permanently stopped Sainus Pharmaceutical Private Limited from using the 'Udaan' trademark. This ruling came after RSPL Health Private Limited filed a case alleging trademark infringement. RSPL Health, known for its 'Ghari' detergent brand, had registered its 'Udan' mark earlier. The court found Sainus Pharma's mark to be identical and deceptively similar to RSPL's registered trademark.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hBDI0m6
via IFTTT

Read More

Govt tightens rules on combinations containing 2 chemical compounds for young children

The government has restricted fixed-dose combinations containing Chlorpheniramine Maleate and Phenylephrine Hydrochloride. These medicines are now prohibited for use in children below four years of age. Manufacturers must clearly display a warning on all associated product packaging. This action follows recommendations from an expert committee and the Drugs Technical Advisory Board. The notification is effective from its publication date in the official gazette.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/g6Cole3
via IFTTT

Read More